The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase III study of atezolizumab (atezo) vs placebo as adjuvant therapy in renal cell carcinoma (RCC) patients (pts) at high risk of recurrence following resection (IMmotion010).
 
Robert Uzzo
Consulting or Advisory Role - Genentech/Roche; Johnson & Johnson; Myriad Genetics; Novartis; Pfizer
Speakers' Bureau - Janssen Oncology
Research Funding - Novartis
 
Axel Bex
No Relationships to Disclose
 
Brian I. Rini
Consulting or Advisory Role - Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Laurence Albiges
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Ipsen (Inst); Novartis; Pfizer; Sanofi
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst); Pfizer (Inst)
 
Cristina Suarez
No Relationships to Disclose
 
Frank Donaldson
Employment - Roche
 
Takashi Asakawa
Employment - Genentech
 
Christina Schiff
Employment - Genentech
Stock and Other Ownership Interests - Genentech
 
Sumanta K. Pal
Honoraria - Astellas Pharma; Medivation; Novartis
Consulting or Advisory Role - Astellas Pharma; Aveo; Bristol-Myers Squibb; Exelixis; Genentech; Myriad Pharmaceuticals; Novartis; Pfizer
Research Funding - Medivation